Volume 81, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


A multidrug-resistant (MDR) clone of (C2A) from Thailand was adapted through serial passage to monkeys. During adaptation, the parasite showed resistance to a single 20 or 40 mg/kg oral dose of mefloquine (MQ). Infection was only cured when MQ was administered orally at 40 mg/kg once in combination with intravenous artesunic acid at 20 mg/kg for 3 days. Similarly, the parasite clone was found to be resistant to quinine, failing at 20 mg/kg orally for 5 days in combination with an experimental dihydrofolate reductase (DHFR) inhibitor (WR297608) at 10, 20, or 40 mg/kg orally for 3 days, and with atovaquone/proguanil at 25 mg/kg for 3 days. This new model will allow testing of new antimalarial compounds or their combinations against a currently circulating MDR strain.


Article metrics loading...

Loading full text...

Full text loading...



  1. Rogers WO, Se T, Tero T, Chim P, Lim P, Muth S, Sochet D, Ariey F, Wongsrichanalai C, 2009. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J 8: 10.
  2. Krudsood S, Patel SN, Tangpukdee N, Thanachartwet W, Leowattana W, Pornpininworakij K, Boggild AK, Looareesuwan S, Kain KC, 2007. Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 76: 655.
  3. Chaijaroendkul W, Bangchang KN, Mungthin M, Ward S, 2005. In vitro antimalarial drug suceptibility in Thai border areas from 1998–2003. Malar J 4: 37.
  4. Cerutti C Jr, Durlacher RR, de Alencar FE, Segurado AA, Pang LW, 1999. In vivo efficary of mefloquine for the treatment of falciparum malaria in Brazil. J Infect Dis 180: 2077–2080.
  5. Wilairatan P, Krudsood S, Treeprasertsuk S, Chalermrut K, Looareesuwan S, 2002. The future outlook of antimalarial drugs and recent work on the treatment of malaria. Arch Med Res 33: 416–421.
  6. Young MD, Porter JA, Johnson CM, 1966. Plasmodium vivax transmitted from man to monkey to man. Nature 153: 1006–1007.
  7. Rossan RN, Christensen HA, Harper JS 3rd, 1981. Adaptation of a Nigerian strain of Plasmodium falciparum to Panamanian Aotus trivirgatus. Am J Trop Med Hyg 30: 289–290.
  8. Rossan RN, Baerg DC, 1987. Adaptation of the Panama II strain of Plasmodium falciparum to Panamanian owl monkeys. Am J Trop Med Hyg 37: 235–240.
  9. Gramzinski RA, Obaldía N III, Jones T, Rossan RN, Collins WE, Garrett DO, Lal A, Hoffman SL, 1999. Susceptibility of Panamanian Aotus lemurinus lemurinus to sporozoite-induced Plasmodium falciparum (Santa Lucia) infection. Am J Trop Med Hyg 61: 19–25.
  10. Porter JA Jr. Plasmodium vivax infections in Aotus trivirgatus. 1971. Am J Trop Med Hyg 20: 535–538.
  11. Young MD, Baerg DC, Rossan RN, 1975. Parasitological review. Experimental monkeys hosts for human plasmodia. Exp Parasitol 38: 136–152.
  12. Young MD, Baerg DC, Rossan RN, 1976. Studies with induced malarias in Aotus monkeys. Lab Anim Sci 26: 1131–1137.
  13. Rossan RN, Harper JS 3rd, Davidson DE Jr, Escajadillo A, Christensen HA, 1985. Comparsion of Plasmodium falciparum infection in Panamanian and Colombian monkeys. Am J Trop Med Hyg 34: 1037–1047.
  14. Fremount HN, Rossan RN, 1990. Antatomical distribution of developing trophozoites and schizonts of Plasmodium vivax in Aotus lemurinus lemurinus and Saimiri sciureus. J Parasitol 76: 428–430.
  15. Obaldía N III, 2007. Clinico-pathological observations on the pathogenesis of severe thrombocytopenia and anemia induced by Plasmodium vivax infections during antimalarial drug efficacy trials in Aotus monkeys. Am J Trop Med Hyg 77: 3–13.
  16. Rossan RN, Young MD, Baerg DC, 1975. Chemotherapy of Plasmodium vivax in Saimiri and Aotus models. Am J Trop Med Hyg 24: 168–173.
  17. Pollack S, Rossan RN, Davidson DE, Escajadillo A, 1987. Desferrioxamine suppresses Plasmodium falciparum in Aotus monkeys. Proc Soc Exp Biol Med 184: 162–164.
  18. Panton LJ, Rossan RN, Escajadillo A, Matsumoto Y, Lee AT, Labroo VM, Kirk KL, Cohen LA, Aikawa M, Howard RJ, 1988. In vitro and in vivo studies of the effects of halogenated histidine analogs on Plasmodium falciparum. Antimicrob Agents Chemother 32: 1655–1659.
  19. Bitonti AJ, Sjoerdsma A, McCann PP, Kyle DE, Oduola AM, Rossan RN, Milhous WK, Davidson DE Jr, 1988. Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine. Science 242: 1301–1303.
  20. Kyle DE, Milhous WK, Rossan RN, 1993. Reversal of Plasmodium falciparum resistance to chloroquine in Panamanian Aotus monkeys. Am J Trop Med Hyg 48: 126–133.
  21. Shmuklarsky MJ, Klayman DL, Milhous WK, Kyle DE, Rossan RN, Ager AL Jr, Tang DB, Heiffer MH, Canfield CJ, Schuster BG, 1993. Comparison of beta-artemether and beta-arteether against malaria parasites in vitro an in vivo. Am J Trop Med Hyg 48: 377–384.
  22. Canfield CJ, Milhous WK, Ager AL, Rossan RN, Sweeney TR, Lewis NJ, Jacobus DP, 1993. PS-15: a potent, orally active anti-malarial from a new class of folic acid antagonists. Am J Trop Med Hyg 49: 121–126.
  23. Posner GH, Oh CH, Webster HK, Ager AL Jr, Rossan RN, 1994. New antimalarial, tricyclic 1,2,4-trioxanes: evaluation in mice and monkeys. Am J Trop Med Hyg 50: 522–526.
  24. Obaldía N III, Rossan RN, Cooper RD, Kyle DE, Nuzum EO, Rieckmann KH, Shanks DG, 1997. WR 238605, chloroquine and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. Am J Trop Med Hyg 56: 508–510.
  25. Oduola AM, Sowunmi A, Milhous WK, Brewer TG, Kyle DE, Gerena L, Rossan RN, Salako LA, Schuster BG, 1998. In vitro and in vivo reversal of chloroquine resistance in Plasmodium falciparum with promethazine. Am J Trop Med Hyg 58: 625–629.
  26. Guan J, Zhang Q, O’Neil M, Obaldía N III, Ager A, Gerena L, Lin AJ, 2005. Antimalarial activity of new pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives. Antimicrob Agents Chemother 49: 4928–4933.
  27. Dow GS, Heady TN, Bhattacharjee AK, Caridha D, Gerena L, Gettayacamin M, Lanteri CA, Obaldía N III, Roncal N, Shearer T, Smith PL, Tungtaeng A, Wolf L, Cabezas M, Yourick D, Smith KS, 2006. Alkylaminoquinolinyl methanols as new antimalarial drugs. Antimicrob Agents Chemother 50: 4132–4143.
  28. Jones TR, Obaldía N III, Gramzinski RA, Hoffman SL, 2000. Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite. Am J Trop Med Hyg 62: 675–680.
  29. Gramzinski RA, Maris DC, Obaldía N III, Rossan R, Sedegah M, Wang R, Hobart P, Margalith M, Hoffman S, 1996. Optimization of antibody responses of a malaria DNA vaccine in Aotus monkeys. Vaccine Research 5: 173–183.
  30. Gramzinski RA, Maris DC, Doolan D, Charoenvit Y, Obaldía N III, Rossan R, Sedegah M, Wang R, Hobart P, Margalith M, Hoffman S, 1997. Malaria DNA vaccines in Aotus monkeys. Vaccine 15: 913–915.
  31. Sim KL, Narum DL, Liang H, Fuhrmann SR, Obaldía N III, Gramzinski R, Aguiar J, Haynes DJ, Moch K, Hoffman SL, 2001. Induction of biologically active antibodies in mice, rabbits, and monkeys by Plasmodium falciparum EBA-175 region II DNA vaccine. Mol Med 7: 247–254.
  32. Jones TR, Gramzinski RA, Aguiar JC, Sim BK, Narum DL, Fuhrmann SR, Kumar S, Obaldía N III, Hoffman SL, 2002. Absence of antigenic competition in Aotus monkeys immunized with Plasmodium falciparum DNA vaccines delivered as a mixture. Vaccine 20: 1675–1680.
  33. Inselburg J, Rossan RN, Escajadillo A, 1989. Growth an immunity conferred by a Plasmodium falciparum temperature sensitive mutant in Panamanian owl monkeys. Am J Trop Med Hyg 40: 465–469.
  34. Jones TR, Obaldía N III, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, Davis HL, Krieg AM, Hoffman SL, 1999. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 17: 3065–3071.
  35. Inselburg J, Bzik DJ, Li WB, Green KM, Kansopon J, Hahm BK, Bathurst IC, Barr PJ, Rossan RN, 1991. Protective immunity induced in Aotus monkeys by recombinant SERA proteins of Plasmodium falciparum. Infect Immun 59: 1247–1250.
  36. Inselburg J, Bathurst IC, Kansopon J, Barchfeld CL, Barr PJ, Rossan RN, 1993. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: adjuvant effects on induction of protective immunity. Infect Immun 61: 2041–2047.
  37. Jones TR, Stroncek DF, Gozalo AS, Obaldía N III, Andersen E, Lucas C, Narum DL, Sim BKL, Hoffman SL, 2002. Anemia in parasite and recombinant protein-immunized Aotus monkeys infected with Plasmodium falciparum. Am J Trop Med Hyg 66: 672–679.
  38. Gramzinski RA, Brazolot Millan CL, Obaldía N III, Hoffman SL, Davis H, 1998. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route and method of administration. Mol Med 4: 109–118.
  39. Ma NS, Rossan RN, Kelley ST, Harper JS, Bedard MT, Jones TC, 1978. Banding patterns of the chromosomes of two new karyotypes of the owl monkey. J Med Primatol 7: 146–155.
  40. Escajadillo A, 1984. Mantenimiento en el laboratorio y algunos usos experimentales del mono nocturno, Aotus. Rev Med Panama 9: 274–287.
  41. Obaldía N III, 1991. Detection of Klebsiella pneumoniae antibodies in Aotus l. lemurinus (Panamanian owl monkey) using an enzyme linked immunoasssay (ELISA) test. Lab Anim 25: 133–141.
  42. Earle WC, Perez M, 1932. Enumeration of parasites in the blood of malarial patients. J Lab Clin Med 17: 1124–1130.
  43. Rossan RN, 1985. Cryopreservation of the blood stages of Plasmodium falciparum and Plasmodium vivax for in vivo studies. Am J Trop Med Hyg 34: 207–208.
  44. Methods in Malaria Research. Fourth edition. (2004) Ljungström I, Perlmann H, Schlichtherle M, and Wahlgren M, eds. Manassas, VA: MR4/ATCC.
  45. Collins WE, 1994. The owl monkey as a model for malaria. Baer JF, Weller RE, Kakoma I, eds. Aotus the Owl Monkey. San Diego, CA: Academic Press Inc., 217–244.
  46. Sullivan JS, Sullivan JJ, Williams A, Grady K, Bounnagseng A, Huber CS, Nace D, Williams T, Galland G, Barnwell JW, Collins WE, 2003. Adaptation of a strain of Plasmodum falciparum from Ghana to Aotus lemurinus griseimembra, A. nancymai and A. vociferans monkeys. Am J Trop Med Hyg 69: 593–600.
  47. Collins WE, Sullivan JS, Hall P, Ruebush TK, Williams A, Grady KK, Bounngaseng A, Nace D, William T, Huber C, Galland G, Barnewell JW, Sullivan JJ, 2007. Adaptation of a multi-drug resistant strain of Plasmodium falciparum from Peru to Aotus lemurinus griseimembra, A. nacymae, and A. vociferans monkeys. Am J Trop Med Hyg 77: 261–265.
  48. Slutsker LM, Khoromana CO, Payne D, Allen CR, Wirima JJ, Heymann DL, Patchen L, Steketee RW, 1990. Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull World Health Organ 68: 53–59.
  49. Thaithong S, 1983. Clones of different sensitivities in drug-resistant isolates of Plasmodium falciparum. Bull World Health Organ 61: 709–712.
  50. Daily JP, Scanfeld D, Pochet N, Le Roch K, Plouffe D, Kamal M, Sarr O, Mboup S, Ndir O, Wypij D, Levasseur K, Thomas E, Tamayo P, Dong C, Zhou Y, Lander ES, Ndiaye D, Wirth D, Winzeler EA, Mesirov JP, Regev A, 2007. Distinct physiological states of Plasmodium falciparum malaria-infected patients. Nature 450: 1091–1095.

Data & Media loading...

  • Received : 02 Sep 2008
  • Accepted : 18 Jun 2009

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error